Sequela of the adult respiratory distress syndrome

The adult respiratory distress syndrome (ARDS) is characterised by hypoxaemia, bilateral pulmonary infiltrates due to increased permeability, pulmonary oedema and, in most but not all instances, reduced lung compliance. The yearly incidence of ARDS is approximately six per 100,000.

ARDS may occur in response to various direct or indirect insults to the lung. Gastric aspiration, bacterial or pneumonia, major trauma, transfusion, and sepsis are among the most common causes (table). A generally standardised approach to the acute, supportive care of these patients has evolved which uses mechanical ventilation and positive end-expiratory pressure (PEEP) but, despite increased experience in caring for these critically ill patients, the mortality of patients with ARDS remains at about 50%.

Death is often due to non-pulmonary causes, multiple organ system failure, or sepsis. Patients who survive an episode of ARDS may be asymptomatic and have normal pulmonary function, or they may have marked dyspnoea and severe physiological abnormalities. This editorial will review (1) the functional and physiological abnormalities seen in survivors of ARDS, (2) the predictors of pulmonary dysfunction in this population, and (3) those aspects of acute patient care which might adversely affect outcome.

Functional and physiological abnormalities

SYMPTOMS

Although many series report that the majority of survivors of ARDS are symptom free,

- in most instances symptoms were not aggressively sought and documented. The larger of these series also appear biased in that they included patients with mild illness. Douglas and Downs identified 54 patients with acute respiratory failure who required mechanical ventilation and PEEP of whom 43 (80%) survived; all survivors were asymptomatic at the time of hospital discharge. Of 15 patients evaluated for 1–30 months after ARDS by Yahav and colleagues none had symptoms, although only 10 of the 15 (66%) required mechanical ventilation, and only seven of these (47%) needed PEEP to maintain oxygenation.

Data from more recent series using a more rigorous definition of ARDS and including a more severely affected patient population suggest that symptom free recovery is somewhat less likely (66% and 50% in the studies by Peters et al and Halevy et al, respectively). Interpretation of the study by Halevy et al, as well as that by Lakshminarayan et al in which 40% of the group was asymptomatic, is complicated by the high incidence of smoking in the two study populations, although only 11% of the patients had symptoms that could be related to smoking before ARDS.

Causes of adult respiratory distress syndrome

Sepsis
Multiple trauma
Hypertransfusion
Multiple fractures
Pneumonias
Aspiration
Pancreatitis
Near drowning
Drug overdose
Inhalation injury

The most systematic evaluation of symptoms after ARDS was by Ghio and associates who found that 21 of 25 patients (84%) studied between 0.5 and 7.5 years after their episode were symptomatic; 55% of those questioned at longer than one year remained so. The most common complaints were cough (44%), sputum production (50%), and dyspnoea (50%). Although 29% of the entire population studied were smokers, smoking status had no association with symptoms. Interestingly, less than half of those with pulmonary complaints had abnormal pulmonary function test results. Conversely, those with abnormal pulmonary function were no more likely to be symptomatic than those with normal pulmonary function. Platypnoea and orthodeoxia that spontaneously resolved over several weeks have also been reported in one patient.

Patients who recover from ARDS are at high risk for upper airway injury that may occur during their recovery. Laryngotracheal stenosis is a well recognised consequence of prolonged intubation, and vocal cord dysfunction is also common. The only symptomatic patient in the study of Elliott et al of 13 survivors of ARDS had dyspnoea because of bilateral vocal cord paralysis. Flow-volume loops should therefore be routinely ordered when evaluating patients with dyspnoea following an episode of ARDS. Since the sensitivity of the flow-volume loop for upper airway abnormalities is not known, an argument may also be made for patients to undergo laryngoscopy, bronchoscopy, or both.

Fortunately few of those who remain symptomatic have respiratory limitation sufficiently severe to impair their lifestyles. Of the 21 symptomatic patients in the study by Ghio et al only three (14%) had moderate or severe physiological abnormalities, and only three of the 26 patients (12%) reported by Peters et al had dyspnoea which interfered with lifestyle. The symptoms of many patients improve during the first year after the episode of ARDS.

SPIROMETRY

Spirometric abnormalities are to be expected early in the post ARDS period (fig 1). In most patients parallel reduc-
tions in forced expiratory volume in one second (FEV₁) and forced vital capacity (FVC) with a preserved FEV₁/FVC value consistent with a restrictive defect are the predominant findings. These abnormalities may occasionally be severe. Forced expiratory volumes tend to improve over time so that normal or near normal values are generally seen by one year.

A subset of ARDS survivors (ranging from 14% to 50%) are left with at least mild airflow limitation (FEV₁/FVC < 65%), forced expiratory flow 25–75% of the vital capacity < 50% predicted) measured up to at least one year after the acute episode. Although in the study by Lakshminarayan and colleagues four of the five patients with airflow limitation were smokers, Elliott et al. found a reduced FEV₁/FVC value in four of 16 non-smokers (25%) one year after their episode of ARDS.

Increased airway resistance is characteristic of the acute phase of ARDS. During recovery, however, increased resistance is uncommon. Although this may, in part, be due to resolution of the airway inflammation, it probably results from the increase in total lung capacity (TLC) that occurs as ARDS resolves. A chronic increase in bronchial reactivity has been observed in response to methacholine or exercise in patients studied more than one year after ARDS. Unfortunately there are no good data that allow identification of those factors which predispose patients with ARDS to airflow limitation or airway reactivity.

LUNG VOLUMES
Lung volumes are reduced in many patients immediately after the episode of ARDS, but tend to improve during the first six months of recovery (fig 2). Elliott and colleagues found that seven of 16 patients (46%) had a reduced TLC when tested less than two months after the onset of ARDS which returned to normal by three months in all instances. Similar observations were made by Peters et al. and by others. An occasional patient may have severely reduced lung volumes which, without apparent explanation, do not improve.

Some patients have residual volumes that remain chronically elevated with TLC being either normal or reduced, and with spirometric testing showing no evidence of airflow limitation. These patients may be manifesting the results of small airway injury during the acute phase of their ARDS. Churg and colleagues recently reported a series of patients who developed progressive radiological signs of air trapping before death. Extensive cyst formation was found at postmortem examination (fig 3). Histologically these cysts were lined by bronchiolar or metaplastic squamous epithelium. Marked bronchiolectasis has also been described. The airflow obstruction that occurs in some patients might have a similar pathophysiological explanation. These findings are in many ways similar to the severe bronchopulmonary dysplasia that occurs as a consequence of the infant respiratory distress syndrome. Bronchopulmonary dysplasia is usually seen in premature infants who require mechanical ventilation and high concentrations of oxygen for prolonged periods. In its most severe form it results in cyst formation, dilated terminal airways, air trapping, and chronic airflow limitation in those who survive.

Because air trapping may be missed when lung volumes are measured by gas dilution techniques, plethysmographic determination is preferred when evaluating patients complaining of dyspnoea following ARDS.

GAS EXCHANGE
Reduced carbon monoxide transfer factor (TLCO) is the most common pulmonary function abnormality seen in patients recovering from ARDS. Soon after the acute episode 75–100% of patients will have normal values. Although some of these patients improve during the first year, 40–80% of those studied had reductions that persisted even after one year. Fortunately, although chronic severe reductions of transfer factor may occur, the degree of abnormality observed is generally mild.

Most patients have normal resting arterial blood gas tensions after recovering from ARDS. Exercise, however, may reveal more subtle gas exchange abnormalities. Elliott and colleagues found that 11 of 13 patients (85%) had an alveolar-to-arterial oxygen difference (A–aDO₂) that was normal at rest (measured one month after ARDS) but increased in all seven of those who were exercised.

![Figure 2](http://thorax.bmj.com/)

**Figure 2** Variation of total lung capacity (TLC) with time in survivors of ARDS. O = single values; ● = multiple values."

![Figure 3](http://thorax.bmj.com/)

**Figure 3** Lung of patient dying from ARDS showing diffuse cystic changes similar to that seen in infants with bronchopulmonary dysplasia.
seven of nine subjects (78%) followed for six to 19 months. Buchser et al. found the A-aDo2 increased with exercise despite normal spirometric values and lung volumes. Alberts et al., in their earlier review of this subject, noted that 48% of patients worsened their oxygenation with exercise.

The proportion of wasted ventilation (Vd/Vt) is often increased early in recovery from ARDS. In many patients the Vd/Vt improves with time, but a substantial number are left with persistently elevated values. Dead space tends to decrease with exercise, although the degree of decrease is reduced over that generally found in normal subjects. After recovery, shunt fraction may be normal or only mildly elevated, although one patient reported by Buchser et al. had a shunt fraction that remained elevated at 15% of the cardiac output more than one year after ARDS.

The failure of TLco to return to normal in most survivors of ARDS contrasts with the improvement in spirometric values and lung volumes in these patients. Low TLco values together with persistent abnormalities in Vd/Vt suggest that destruction or obstruction of the pulmonary vasculature may have occurred. There are abundant histological data to indicate that vascular loss does occur in the acute phase of ARDS. Bachofen and Weibel found striking reductions in the numbers of pulmonary capillaries seen in specimens obtained after the first 24 hours of ARDS. Extensive thrombosis of pulmonary arteries has also been shown by both antemortem and postmortem arteriography (fig 5). Snow et al. estimated morphometrically that the density of precapillary arterioles was reduced by 50%. Extensive occlusion of the microvasculature by fibrin thrombi and non-thrombotic vascular obstruction caused by intimal proliferation and endothelial cell swelling is also seen in acute ARDS. Early vascular occlusion may correlate with the severity of ARDS and with survival from the acute event. In a study of six patients recovering from ARDS who underwent exercise testing, Buchser calculated a reduced pulmonary capillary blood volume. At this time a complete understanding of the causes of gas exchange abnormalities after ARDS is lacking. There are inadequate data available to conclude that finding these abnormalities in the immediate period after ARDS is predictive of long term pulmonary dysfunction.

Predictors of pulmonary dysfunction
It is difficult to attach prognostic importance to demographic or other patient characteristics that are unrelated to the episode of ARDS. In most studies patient numbers are too small to draw conclusions regarding whether the event associated with ARDS is correlated with outcome. Ghio and colleagues found no relationship between the precipitating cause and long term abnormalities of pulmonary function. Case reports have suggested that patients with ARDS caused by viral pneumonia may be predisposed to developing fibrosis and suffering long term functional abnormality.

Although several studies have suggested that older age predisposes to persistent abnormality of pulmonary function, Ghio and associates also recently noted that patients younger than 20 had an increased risk of residual dysfunction.

The acute cellular response in ARDS is a neutrophilic alveolitis. Because cigarette smoking also increases the bronchoalveolar lavage neutrophil content, particularly in the setting of chronic bronchitis, smoking might be expected to contribute to more severe acute disease and to worsen pulmonary function in survivors. Unfortunately this supposition is not supported by the available data. Elliott et al. and Peters et al. found no significant differences in follow up measurements of TLC, FVC, FEV1, or TLco between smokers and non-smokers, although the maximum improvement in pulmonary function did seem to take longer in smokers.

Nosocomial bacterial pneumonia is common in ARDS and is associated with worse acute pulmonary function and

---

**Figure 4** Variation of carbon monoxide transfer factor (TLco) with time in survivors of ARDS. ○ = single values; ● = multiple values.

**Figure 5** (A) Postmortem arteriogram of normal adult lung; the pleural surface is at the bottom. (B) Arteriogram of a patient with early ARDS showing reduced filling of small arteries. Magnification × 2.4, increased to 158% in origination.
with increased mortality. In survivors of ARDS there is evidence that infectious complications worsen pulmonary function after recovery. Peters and associates found a significant association between sepsis and a reduced TLCO at six months compared with a group that did not develop sepsis. Although anecdotal reports have also suggested an association between necrotising Gram negative pneumonia and subsequent physiological impairment, Peters et al found no relation between nosocomial pneumonia and chronic pulmonary function.

The severity of ARDS is probably the only variable having prognostic importance for subsequent pulmonary dysfunction. Ghioto et al and Elliott et al in studies of 41 and 16 survivors of ARDS respectively, reported that subsequent pulmonary function correlated with the degree of abnormality in thoracic compliance, pulmonary artery pressure, and shunt fraction measured during the first days of illness. Patients with chronic abnormalities of pulmonary function required longer mechanical ventilation and higher levels of PEEP. Peters et al found that patients with increased pulmonary vascular resistance, pulmonary arterial pressures, and A–ADo2 measured on days 4–7 of their acute episode had lower values of TLCO. The presence of barotrauma and the need for an Fio2 >0.6 for longer than 24 hours has been associated with a reduced TLCO measured one year later. Two other small studies found no correlation between abnormalities of lung function and (1) the severity of ARDS, (2) the duration of mechanical ventilation, (3) the duration of PEEP therapy, or (4) the initial arterial oxygen tension. Despite these contradictions most of the data support the association between the severity of ARDS and chronic pulmonary dysfunction.

**Effect of management of ARDS on subsequent pulmonary function**

Care of patients with ARDS is often described as being “supportive” in that no specific treatment for the pathophysiological abnormalities – that is, acute lung inflammation – has been described. It is important to consider the possibility that some aspects of this support, in particular mechanical ventilation and hyperoxia, may actually contribute to the severity of the acute episode and therefore potentially affect the degree of pulmonary dysfunction in the survivors.

**Lung Volume and Positive End Expiratory Pressure**

Numerous studies in animals have shown that positive pressure ventilation at high inspiratory pressures causes acute lung injury. Two important studies showed that it is the large tidal volumes generated by the increased inspiratory pressure, rather than the high pressure itself, that is responsible for the injury. Hernandez et al compared the effects of ventilating two groups of rabbits with high peak inspiratory pressures. One group was placed in full body plaster casts and the second group was not. The injury produced by high peak inspiratory pressure in the control group (manifested as increased microvascular permeability) was completely prevented by the plaster cast which limited the end inspiratory volume. Dreyfuss and coworkers have also similar findings using chest strapping to control inspiratory volume.

The tidal volume required to cause lung injury in animals with otherwise normal lungs is generally higher than that used in clinical practice. Smaller tidal volumes can cause this type of damage in patients with ARDS because the lung inflammation, oedema and atelectasis are not homogeneously distributed. Accordingly, there are significant differences in local alveolar compliance such that areas of normal lung (that have normal compliance) will expand to a greater extent than areas that are injured (with lower compliances). Although no well designed trials have investigated whether ventilating with low tidal volumes can reduce mortality or acute or long term morbidity in humans, a recent retrospective uncontrolled study suggests that this may be the case. Hickling and colleagues reported the results of 50 patients with severe ARDS who were ventilated with low tidal volumes. The partial pressure of arterial CO2 was allowed to rise to a mean of 60 mm Hg. The mortality in these patients was only 16%, considerably better than other published results. Decreased mortality has also been reported using “permissive hypercapnia” in ventilated patients with status asthmaticus.

If tidal volume is kept constant, PEEP will increase peak and mean airway pressure as well as end inspiratory and end expiratory lung volumes. Accordingly, the level of PEEP can also cause or contribute to lung injury. Because the most severe cases of ARDS generally are treated with higher levels of PEEP to prevent hypoxaemia, it is difficult to distinguish between deleterious effect of PEEP and the effects of ARDS itself.

Most experimental evidence argues that low levels of PEEP protect the lung from ventilator associated injury. Webb and Tierney first noted in animals that 5 cm H2O of PEEP reduced the amount of oedema caused by ventilation at high inflation pressures (and volumes). This protective effect has been supported by other investigators using models of both hydrostatic oedema and increased permeability oedema. Although PEEP does not reduce lung water and may actually increase it, it redistributes the oedema away from alveoli into the interstitium, and also prevents depletion of surfactant that results from lungs being ventilated at low expiratory volumes.

The level of PEEP has been shown by some to correlate inversely with long term pulmonary function. Elliott and coworkers reported that survivors of ARDS with abnormalities of lung function were more likely to have received higher levels of PEEP than those with normal function. In contrast, Peters et al reported that higher levels of PEEP during the first week of ventilator support were associated with more normal values of TLC and FVC measured more than six months after the acute episode. Patient characteristics, predisposing conditions, and severity of disease do not seem to explain these differences.

Fio2, the level to which Fio2 must be raised to correct hypoxaemia is another marker for the severity of the acute episode. The effect of oxygen on the course of patients with ARDS is difficult to ascertain because those with the worst disease require the most intensive support. In addition, there is no histological difference between ARDS and oxygen toxicity. Ample animal data suggest that hyperoxia can create or worsen pulmonary injury. In animal models of oleic acid-induced acute lung injury, breathing 40% or 50% oxygen causes no additional lung injury while 100% oxygen results in progressive oedema and dysfunction. There are obvious interests in a study examining the effects of chronic hyperoxia on normal subjects. Because there are considerable species variabilities with regard to susceptibility to oxygen toxicity, the relevance of animal studies to patients with ARDS is uncertain. In humans, Van de Water et al found no significant physiological differences between healthy individuals breathing 100% oxygen for 6–12 hours and those breathing air. Singer et al reported...
Summary and conclusions
Most survivors of ARDS have persistent milder reductions of TLco even as long as a year after their episode. The lung volumes and flows return to normal in most instances, although a subset of patients will have persistent impairment. Both obstructive and restrictive deficits may be seen. This group may be predicted by the degree of acute lung injury assessed by the level of 

In the first year after ARDS most physiological abnormalities will improve, but if deficits persist at one year further improvement is unlikely. Although many patients report dyspnoea following ARDS, the symptom does not correlate with abnormalities of pulmonary function. The possibility that conventional management may augment the degree of acute injury and worsen outcome must be considered. The effects of chronic hyperoxia in humans with acute lung injury or those of high levels of PEEP compared with low levels are not known. Exploring new ventilator management strategies while we await more specific treatment directed at the primary problem of acute lung inflammation will hopefully reduce acute mortality as well as acute and chronic morbidity.

Pulmonary and Critical Care Medicine, University of Washington Medical Center, Seattle, Washington 98195, USA

Reprint requests to Dr R K Albert.

9 Douglas M, Downs J. Pulmonary function following severe acute respiratory failure and high levels of positive end-expiratory pressure. Chest 1977;71:18-23.
Sequelae of the adult respiratory distress syndrome


